Pharmaceutical Stocks To Watch Now - May 21st

D-Wave Quantum, Eli Lilly and Company, Thermo Fisher Scientific, Pfizer, and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are equity shares of companies engaged in the research, development, manufacturing and marketing of prescription and over-the-counter medications. Their performance is driven by factors such as clinical trial outcomes, regulatory approvals, patent protections and market demand. Because of high research costs, regulatory hurdles and patent cliffs, these stocks can exhibit significant volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

D-Wave Quantum (QBTS)

D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.

Shares of QBTS stock traded down $0.88 during trading hours on Wednesday, reaching $15.68. 184,709,089 shares of the company's stock were exchanged, compared to its average volume of 40,456,402. The business has a fifty day moving average price of $8.34 and a 200-day moving average price of $6.35. The stock has a market capitalization of $4.57 billion, a P/E ratio of -37.55 and a beta of 0.90. D-Wave Quantum has a fifty-two week low of $0.75 and a fifty-two week high of $19.43.

Read Our Latest Research Report on QBTS

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE LLY traded down $18.20 during trading hours on Wednesday, reaching $728.81. The stock had a trading volume of 2,148,636 shares, compared to its average volume of 3,602,270. The business's fifty day moving average is $795.44 and its two-hundred day moving average is $804.82. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market cap of $690.72 billion, a price-to-earnings ratio of 62.32, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53.

Read Our Latest Research Report on LLY

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Thermo Fisher Scientific stock traded down $14.12 during mid-day trading on Wednesday, hitting $399.64. 1,643,304 shares of the company were exchanged, compared to its average volume of 1,845,096. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average of $449.99 and a 200 day moving average of $508.22. Thermo Fisher Scientific has a 1-year low of $390.50 and a 1-year high of $627.88. The company has a market capitalization of $150.86 billion, a PE ratio of 24.25, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82.

Read Our Latest Research Report on TMO

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Pfizer stock traded down $0.37 during mid-day trading on Wednesday, hitting $23.16. 22,870,080 shares of the company were exchanged, compared to its average volume of 40,958,664. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a fifty day moving average of $23.56 and a 200 day moving average of $25.27. Pfizer has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a market capitalization of $131.64 billion, a PE ratio of 16.45, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Read Our Latest Research Report on PFE

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Shares of NVO stock traded up $0.05 during trading hours on Wednesday, hitting $68.25. 6,504,958 shares of the company's stock were exchanged, compared to its average volume of 6,638,312. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market cap of $306.26 billion, a price-to-earnings ratio of 20.76, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The stock's 50-day moving average is $67.00 and its 200-day moving average is $83.76. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $148.15.

Read Our Latest Research Report on NVO

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.